Minerva Neurosciences, Inc
Symbol: NERV (NASDAQ)
4.66
▼ (-4.31%) -0.210
Company Description:
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
Key Stats
- Today's Open: $4.53
- Today's High: $5.028
- Today's Low: $4.47
- Today's Volume: 881.57K
- Yesterday Close: $4.87
- Yesterday High: $5.61
- Yesterday Low: $4.82
- Yesterday Volume: 727.50K
- Last Min Volume: 25
- Last Min High: $4.66
- Last Min Low: $4.66
- Last Min VWAP: $4.66
Company Profile
- Name: Minerva Neurosciences, Inc
- Website: https://www.minervaneurosciences.com
- Listed Date: 2014-07-01
- Location: WALTHAM, MA
- Market Status: Active
- CIK Number: 0001598646
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $32.87M
- Round Lot: 100
- Outstanding Shares: 6.99M
- Asset Type: CS
RECENT FILINGS FOR NERV
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-10-22 | 8-K | View |
| 2025-08-14 | 10-Q | View |
| 2025-05-13 | 10-Q | View |
| 2025-04-29 | 10-K/A | View |
| 2025-04-21 | 10-K/A | View |
| 2025-03-19 | 8-K | View |
| 2025-02-25 | 10-K | View |
| 2025-01-13 | 8-K | View |
| 2024-12-06 | 4 | View |
| 2024-12-06 | 4 | View |
| 2024-12-06 | 4 | View |
| 2024-12-06 | 4 | View |
| 2024-12-06 | 4 | View |
| 2024-12-06 | 4 | View |
| 2024-12-06 | 4 | View |
| 2024-12-05 | 8-K | View |
| 2024-11-12 | SC 13G/A | View |
| 2024-11-05 | 10-Q | View |
| 2024-10-22 | ARS | View |
| 2024-10-22 | DEFA14A | View |
Latest News on NERV